GSK Partners With Myogen Ahead Of Ambrisentan Launch

GlaxoSmithKline will commercialize Myogen’s selective endothelin receptor antagonist for pulmonary arterial hypertension outside the U.S. following approval; Myogen will take over marketing of GSK’s Flolan in the U.S.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet